AIM ImmunoTech Announces Positive Results from AMP-518 Study
OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) has shared significant findings from their recent clinical trial, AMP-518, which evaluated Ampligen as a potential treatment for individuals suffering from post-COVID conditions, particularly fatigue. The results have been officially posted on ClinicalTrials.gov.
Clinical Findings Highlight Ampligen's Potential
CEO Thomas K. Equels expressed optimism about the outcomes of the AMP-518 study, which supports AIM's belief that Ampligen could benefit those with moderate to severe fatigue post-COVID. The company's extensive analysis has identified a group of patients likely to see the most significant improvements from future Ampligen treatments.
Link Between Long COVID and Myalgic Encephalomyelitis
Recent evaluations reveal a compelling connection between Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Statistics indicate that the number of patients meeting the diagnostic criteria for ME/CFS has drastically increased since the pandemic began, emphasizing the urgent need for effective treatments. AIM aims to utilize this research to drive forward their clinical initiatives.
Study Parameters and Results
AIM previously reported positive topline results from the AMP-518 Phase 2 clinical trial. In this study, patients receiving Ampligen demonstrated a notable ability to walk farther during the Six-Minute Walk Test (6MWT) compared to those who were given a placebo. This assessment measured how far patients could walk in six minutes, helping establish a clear baseline. After 13 weeks of treatment, Ampligen participants with initial 6MWT scores under 205 meters improved their distance significantly.
Future Directions for Therapeutic Development
CEO Equels emphasizes the importance of addressing the ongoing epidemic of post-COVID fatigue. With the growing number of individuals potentially affected by this condition, AIM ImmunoTech is committed to collaborating with public sector entities to explore innovative therapeutic options. Future clinical trials are expected to focus specifically on those suffering from moderate or severe symptoms related to COVID fatigue.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an innovative immuno-pharmaceutical company dedicated to developing therapeutics for various cancers, viral diseases, and immune disorders, including COVID-19. Their leading investigational drug, Ampligen, is being tested for its effectiveness across a spectrum of serious health challenges.
Frequently Asked Questions
What is AIM ImmunoTech's recent clinical trial about?
AIM ImmunoTech's latest clinical trial, AMP-518, focuses on the efficacy of Ampligen in treating post-COVID fatigue and conditions.
What were the findings from the AMP-518 study?
The study revealed that Ampligen-treated individuals improved their walking distance significantly compared to those on placebo, indicating its potential benefits.
Why is there an increase in ME/CFS cases?
The prevalence of ME/CFS diagnoses has increased substantially, largely attributed to the long-term effects following COVID-19 infections.
How is AIM ImmunoTech addressing these health challenges?
AIM is committed to developing effective therapies by conducting further clinical trials and collaborating with public health sectors.
Where can I find more information on AIM ImmunoTech?
More information can be found on the official AIM ImmunoTech website and their various social media channels.
